“Modelling and functional analysis of clonal Evolution in Leishmania – possible role of non-coding RNAs and RNA modification”
Recipient: Gerald Spaeth, coordinator Agency: Campus France, MEAE, Type: Bi-national program France/Israel, 04/2018 – 03/2020 Leishmaniasis is among the five most serious parasitic diseases worldwide. The cutaneous form of the disease is prevalent in […]
ANR Patho-Methylome – The role of lysine methylation in host-pathogen interactions
The interaction between two eukaryotic genomes provides a fascinating example of co-evolution of host-parasite interactions. Two genomes, two epigenomes, two cellular systems living together. Our proposal focuses on the fascinating features of the interaction […]
FP7 Anti-Parasitic Drug Discovery in Epigenetics (A-ParaDDisE)
We will employ a target-based strategy for the development of novel drug leads against epigenetic targets in schistosomiasis, leishmaniasis, Chagas disease and malariafocusing on key histone modifying enzymes (HME), in particular those involved in […]
2019Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening, Sci Rep 2019 Jan;9(1):438.
2017The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery, PLoS Negl Trop Dis 2017 Jun;11(6):e0005480.
2016Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth, Int J Parasitol Drugs Drug Resist 2017 04;7(1):42-50.